Content related to Backstory: An 18-Year Journey From Idea to FDA-Approved Therapy

A CHLA clinical trial finds that N-acetylcysteine may be a promising next-generation therapy to reduce the risk of cisplatin-induced hearing loss.

The machine learning model quantifies a child’s individual risk of developing permanent hearing loss from the chemotherapy drug cisplatin.

A new survey endorses the value of cancer survivorship care but finds that many adult patients aren’t accessing it.

Hunter never let his acute lymphoblastic leukemia diagnosis define him—but today, he proudly wears the title “survivor” in support of cancer research.

A multi-center clinical trial demonstrates how new reporting tools help symptom management and intervention for children receiving cancer treatment.

A CHLA oncologist is leading new research to improve outcomes for children, adolescents and young adults with relapsed or treatment-resistant germ cell tumors.

Facing a new diagnosis? A pediatric oncologist explains what the care journey looks like for acute lymphoblastic leukemia, the most common form of childhood cancer.

Five important questions that parents should ask about participating in a cancer clinical trial.

Study results are promising for an investigational drug to prevent bleeding in patients with a severe clotting disorder.